恩华药业(002262)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002262 恩华药业

交易中 12-15 13:40:27

{"stockData":{"symbol":"002262","market":"SZ","secType":"STK","nameCN":"恩华药业","latestPrice":24.69,"timestamp":1765777227000,"preClose":24.53,"halted":0,"volume":4137889,"delay":0,"changeRate":0.0065,"floatShares":884000000,"shares":1016000000,"eps":1.2104,"marketStatus":"交易中","change":0.16,"latestTime":"12-15 13:40:27","open":24.52,"high":24.79,"low":24.4,"amount":102000000,"amplitude":0.0159,"askPrice":24.7,"askSize":363,"bidPrice":24.69,"bidSize":335,"shortable":0,"etf":0,"ttmEps":1.2104,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1765782000000},"marketStatusCode":2,"adr":0,"adjPreClose":24.53,"symbolType":"stock","openAndCloseTimeList":[[1765762200000,1765769400000],[1765774800000,1765782000000]],"highLimit":26.98,"lowLimit":22.08,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1015786583,"isCdr":false,"pbRate":3.07,"roa":"--","peRate":20.398215,"roe":"14.31%","epsLYR":1.13,"committee":0.28869,"marketValue":25080000000,"turnoverRate":0.0047,"status":0,"floatMarketCap":21824000000},"requestUrl":"/m/hq/s/002262/tweets","defaultTab":"tweets","newsList":[{"id":"2588014824","title":"恩华药业（002262）披露补选1名独立董事公告，12月03日股价上涨0.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588014824","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588014824?lang=zh_cn&edition=full","pubTime":"2025-12-03 17:17","pubTimestamp":1764753465,"startTime":"0","endTime":"0","summary":"截至2025年12月3日收盘，恩华药业报收于24.45元，较前一交易日上涨0.74%，最新总市值为248.36亿元。近日，江苏恩华药业股份有限公司发布公告称，公司于2025年12月3日召开第七届董事会第五次会议，审议通过补选1名独立董事的议案。本次补选后，公司独立董事人数将由3人增至4人，董事会人数增至10人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300026591.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262","LU2148510915.USD","BK0070","BK0188","LU1064130708.USD","LU1064131003.USD","BK0239"],"gpt_icon":0},{"id":"2584950293","title":"股市必读：恩华药业（002262）11月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2584950293","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584950293?lang=zh_cn&edition=full","pubTime":"2025-11-19 02:55","pubTimestamp":1763492112,"startTime":"0","endTime":"0","summary":"截至2025年11月18日收盘，恩华药业报收于24.3元，上涨0.33%，换手率0.55%，成交量4.9万手，成交额1.19亿元。董秘最新回复投资者： 您好！请问截至10月31日公司股东人数是多少，谢谢！根据信息披露相关规则，公司股东户数等相关信息会在公司定期报告中进行披露。当日关注点来自交易信息汇总：11月18日主力资金净流出1022.53万元，显示主力短期减持动向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900001248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK0188","LU1064131003.USD","BK0239","002262","LU1064130708.USD","BK0070"],"gpt_icon":0},{"id":"2581175441","title":"股市必读：恩华药业（002262）11月4日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2581175441","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581175441?lang=zh_cn&edition=full","pubTime":"2025-11-05 01:07","pubTimestamp":1762276037,"startTime":"0","endTime":"0","summary":"截至2025年11月4日收盘，恩华药业报收于24.17元，下跌1.95%，换手率1.13%，成交量9.97万手，成交额2.42亿元。董秘最新回复投资者： 请问贵公司在国家医药集采政策中中标之后，是否出现盈利空间受限之类的情况？其回款账期由国家集采政策相关规定予以明确。当日关注点来自交易信息汇总：11月4日主力资金净流出3598.87万元，占总成交额14.88%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500000868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0239","BK0070","002262","LU1064130708.USD","LU2148510915.USD","BK0188"],"gpt_icon":0},{"id":"2578725656","title":"股市必读：恩华药业(002262)股东户数3.74万户，较上期减少14.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578725656","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578725656?lang=zh_cn&edition=full","pubTime":"2025-10-27 01:14","pubTimestamp":1761498851,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，恩华药业报收于25.5元，下跌2.0%，换手率1.22%，成交量10.79万手，成交额2.76亿元。交易信息汇总资金流向10月24日主力资金净流出4021.52万元；游资资金净流入18.16万元；散户资金净流入4003.36万元。股本股东变化股东户数变动截至2025年9月30日，公司股东户数为3.74万户，较6月30日减少6196.0户，减幅为14.2%。户均持股数量由上期的2.33万股增至2.71万股，户均持股市值为73.82万元。会议以3票赞成、0票反对、0票弃权审议通过《2025年第三季度报告》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700000368.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0239","BK0070","002262","LU1064130708.USD","LU2148510915.USD","BK0188"],"gpt_icon":0},{"id":"2578102683","title":"恩华药业（002262）2025年三季报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2578102683","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578102683?lang=zh_cn&edition=full","pubTime":"2025-10-26 06:12","pubTimestamp":1761430322,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期恩华药业发布2025年三季报。截至本报告期末，公司营业总收入44.71亿元，同比上升7.85%，归母净利润11.06亿元，同比上升8.42%。按单季度数据看，第三季度营业总收入14.61亿元，同比上升5.7%，第三季度归母净利润4.06亿元，同比上升3.67%。本报告期恩华药业盈利能力上升，毛利率同比增幅3.08%，净利率同比增幅0.74%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600001957.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262"],"gpt_icon":0},{"id":"2577596794","title":"恩华药业(002262)9月30日股东户数3.74万户，较上期减少14.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577596794","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577596794?lang=zh_cn&edition=full","pubTime":"2025-10-24 17:12","pubTimestamp":1761297165,"startTime":"0","endTime":"0","summary":"证券之星消息，近日恩华药业披露，截至2025年9月30日公司股东户数为3.74万户，较6月30日减少6196.0户，减幅为14.2%。在化学制药行业个股中，恩华药业股东户数高于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.23万户。从股价来看，2025年6月30日至2025年9月30日，恩华药业区间涨幅为30.9%，在此期间股东户数减少6196.0户，减幅为14.2%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400030397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU1064131003.USD","002262","BK0188","BK0070","LU1064130708.USD","BK0239"],"gpt_icon":0},{"id":"2577466593","title":"恩华药业(002262.SZ)发布前三季度业绩，归母净利润11.06亿元，同比增长8.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577466593","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577466593?lang=zh_cn&edition=full","pubTime":"2025-10-24 16:23","pubTimestamp":1761294213,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恩华药业(002262.SZ)发布2025年三季度报告，前三季度，公司实现营业收入44.71亿元，同比增长7.85%。归属于上市公司股东的净利润11.06亿元，同比增长8.42%。归属于上市公司股东的扣除非经常性损益的净利润11.09亿元，同比增长7.59%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1359329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"恩华药业(002262.SZ)发布前三季度业绩，归母净利润11.06亿元，同比增长8.42%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002262"],"gpt_icon":0},{"id":"2570830852","title":"国金证券：给予恩华药业买入评级，目标价36.47元","url":"https://stock-news.laohu8.com/highlight/detail?id=2570830852","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570830852?lang=zh_cn&edition=full","pubTime":"2025-09-27 10:50","pubTimestamp":1758941424,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司甘坛焕近期对恩华药业进行研究并发布了研究报告《自研新药报产迎破局，创新步入收获期》，给予恩华药业买入评级，目标价36.47元。我们选取麻醉代表药企进行可比参考,叠加考虑到公司创新药管线陆续兑现，给予公司2025年28XPE，每股目标价约36.47元。首次覆盖，给予“买入”评级。最新盈利预测明细如下：该股最近90天内共有9家机构给出评级，买入评级9家；过去90天内机构目标均价为33.33。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092700006279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262"],"gpt_icon":0},{"id":"2569773805","title":"恩华药业：盐酸他喷他多片为仿制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2569773805","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569773805?lang=zh_cn&edition=full","pubTime":"2025-09-24 15:07","pubTimestamp":1758697637,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业(002262)09月24日在投资者关系平台上答复投资者关心的问题。投资者提问：盐酸他喷他多片属于新药范畴，请问是完全自主配置。还是需要原研药加入进去，国外原研药现在占国内多少市场份额。另外请问普通投资者能否进贵公司参观了解。恩华药业回复：答：盐酸他喷他多片为仿制药，目前该品种国内只有宜昌人福药业有限责任公司于2025年2月份获得批准。投资者如有到公司参观的需求，需提前预约，根据公司的工作安排情况集中统一接待。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092400021772.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0188","002262","BK0239"],"gpt_icon":0},{"id":"2568258037","title":"恩华药业(002262.SZ)：盐酸他喷他多片获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2568258037","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568258037?lang=zh_cn&edition=full","pubTime":"2025-09-19 15:51","pubTimestamp":1758268273,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恩华药业(002262.SZ)公告，公司近日获得国家药品监督管理局核准签发的化学药品盐酸他喷他多片的《药品注册证书》。盐酸他喷他多片用于治疗成人患者严重到需要使用阿片类药物治疗的急性疼痛，以及替代治疗不能充分缓解的急性疼痛。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1347252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"恩华药业(002262.SZ)：盐酸他喷他多片获药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002262","BK0188","BK0070","BK0239"],"gpt_icon":0},{"id":"2567177680","title":"恩华药业：参股公司江苏好欣晴IPO工作正在有序推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2567177680","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567177680?lang=zh_cn&edition=full","pubTime":"2025-09-16 15:57","pubTimestamp":1758009434,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业(002262)09月16日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，为什么公司不披露好欣晴在h股还是在美股上市呢？别的公司比如若羽臣都是大大方方的披露的筹备h股上市， 请问详细的筹备工作大概什么时候递交招股书，今年还是明年恩华药业回复：答：感谢您对公司的关注。参股公司江苏好欣晴IPO工作正在有序推进，具体情况以公司披露的信息为准。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091600022826.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262","BK0188","BK0070","BK0239"],"gpt_icon":0},{"id":"2567194524","title":"恩华药业涨6.07%，开源证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2567194524","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567194524?lang=zh_cn&edition=full","pubTime":"2025-09-15 16:26","pubTimestamp":1757924795,"startTime":"0","endTime":"0","summary":"今日恩华药业涨6.07%，收盘报28.64元。2025年7月31日，开源证券研究员余汝意,刘艺发布了对恩华药业的研报《公司信息更新报告：神经类业务快速增长，创新管线逐步兑现》，该研报对恩华药业给出“买入”评级。研报中预计2025-2027年归母净利润为12.94、14.95、17.46亿元，EPS为1.27、1.47、1.72元/股，当前股价对应PE为17.5、15.2、13.0倍，维持“买入”评级。此外，西南证券研究员杜向阳,陈辰，东吴证券研究员朱国广近期也对该股发布了研报，同样给出“买入”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091500020568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262","161027"],"gpt_icon":0},{"id":"2562783720","title":"恩华药业：公司参股公司江苏好欣晴IPO工作正在有序推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2562783720","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562783720?lang=zh_cn&edition=full","pubTime":"2025-08-26 15:57","pubTimestamp":1756195038,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业(002262)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请介绍一下好欣晴IPO进展情况恩华药业回复：答：感谢您对公司的关注。公司参股公司江苏好欣晴IPO工作正在有序推进，具体情况以公司披露的信息为准。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082600029669.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0070","002262","BK0239"],"gpt_icon":0},{"id":"2562126227","title":"股市必读：恩华药业（002262）8月25日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2562126227","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562126227?lang=zh_cn&edition=full","pubTime":"2025-08-26 03:59","pubTimestamp":1756151949,"startTime":"0","endTime":"0","summary":"截至2025年8月25日收盘，恩华药业报收于25.05元，下跌0.99%，换手率2.18%，成交量19.28万手，成交额4.83亿元。董秘最新回复投资者： 请问公司截止今年8月20号的股东总户数是多少户？交易信息汇总8月25日，恩华药业的资金流向情况如下：主力资金净流出611.34万元；游资资金净流入2455.2万元；散户资金净流出1843.86万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082600007096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262","BK0239","BK0070","BK0188"],"gpt_icon":0},{"id":"2560169627","title":"恩华药业：解除限售股票授予成本为11.51元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2560169627","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560169627?lang=zh_cn&edition=full","pubTime":"2025-08-19 16:27","pubTimestamp":1755592049,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业(002262)08月19日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，2025年8月14日解禁股226.45万股的成本多少？谢谢！恩华药业回复：公司本次解除限售的226.4451万股系公司2024年限制性股票激励计划授予的限制性股票第一个解除限售期的股票，其授予成本为11.51元/股。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081900027560.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262","BK0239","BK0188","BK0070"],"gpt_icon":0},{"id":"2560977477","title":"恩华药业：公司高度重视市值管理工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2560977477","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560977477?lang=zh_cn&edition=full","pubTime":"2025-08-18 16:21","pubTimestamp":1755505274,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业08月18日在投资者关系平台上答复投资者关心的问题。比如，哪一年预期达到500亿元的总市值？公司上市后各年持续进行现金分红，累计派现15.77亿元。公司高度重视公司市值管理工作，专门制定了《江苏恩华药业股份有限公司市值管理制度》明确主体责任，积极把公司做大做强，保持公司业绩可持续高质量稳定增长，积极支持维护资本市场平稳运行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081800021496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262","BK0188","BK0070","BK0239"],"gpt_icon":0},{"id":"2556802497","title":"恩华药业：NH600001乳状注射液临床试验受试者已全部出组","url":"https://stock-news.laohu8.com/highlight/detail?id=2556802497","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556802497?lang=zh_cn&edition=full","pubTime":"2025-08-04 17:33","pubTimestamp":1754299989,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业(002262)08月04日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请问公司NH600001提交NDA的进展情况？恩华药业回复：答：NH600001原料药上市登记注册申请已于2025.07.29受理。NH600001乳状注射液临床试验研究受试者已全部出组，目前正在进行数据统计工作，待完成临床总结报告后将提交上市注册申请。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080400024138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262","BK0188","BK0070","BK0239"],"gpt_icon":0},{"id":"2556896472","title":"恩华药业：临床试验数据涉及知识产权和公司商业策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2556896472","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556896472?lang=zh_cn&edition=full","pubTime":"2025-08-01 17:24","pubTimestamp":1754040268,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业(002262)08月01日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司得一些关键临床试验得数据为什么不发布呢？ 尤其是一些三期和二期结束得试验， 没有像其他公司一样发布试验结果数据是不是可以理解为， 试验得结果不太行？恩华药业回复：基于临床试验数据涉及知识产权和公司商业策略的考量，并遵守信息披露规则的要求，公司在定期报告及临时公告中及时披露了新药研发进展及取得的成果等重要信息。您对公司的关注和支持将推动我们更好地履行责任。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080100029764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK1141","BK0188","BK0070","002262","BK1576","BK0239","03347"],"gpt_icon":0},{"id":"2556886752","title":"研报掘金丨东吴证券：维持恩华药业“买入”评级，创新药梯队蓄势待发","url":"https://stock-news.laohu8.com/highlight/detail?id=2556886752","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556886752?lang=zh_cn&edition=full","pubTime":"2025-08-01 15:23","pubTimestamp":1754033003,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0276","BK0070","09939","BK0183","BK1515","BK0012","BK1574","06978","BK1161","BK4134","BK0239","002262","III","159938","601555","BK0009","BK0028","159992","BK0188"],"gpt_icon":0},{"id":"2555062727","title":"恩华药业：公司自2023年起没有产品出口欧盟国家","url":"https://stock-news.laohu8.com/highlight/detail?id=2555062727","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555062727?lang=zh_cn&edition=full","pubTime":"2025-07-30 07:30","pubTimestamp":1753831829,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业(002262)07月30日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司自2023年起是否出口欧盟国家恩华药业回复：感谢您对公司的关注！公司自2023年起没有产品出口欧盟国家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025073000005278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0188","BK0239","FSXEmain","002262","FESXmain"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765777228311,"stockEarnings":[{"period":"1week","weight":-0.0024},{"period":"1month","weight":-0.0188},{"period":"3month","weight":-0.0915},{"period":"6month","weight":0.1598},{"period":"1year","weight":-0.0358},{"period":"ytd","weight":0.024}],"compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0277},{"period":"3month","weight":0.0048},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1236},{"period":"ytd","weight":0.1604}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恩华药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"37430人(较上一季度减少14.20%)","perCapita":"23614股","listingDate":"2008-07-23","address":"江苏省徐州市鼓楼区经济技术开发区杨山路18号","registeredCapital":"101578万元","survey":"　　江苏恩华药业股份有限公司的主营业务是医药生产、研发和销售。公司的主要产品是力月西、福尔利、芬特、阿纷尼、恩利泽、欧立罗、泊得乐、必和、碳酸锂缓释片、维必朗、阿普唑仑片、恩卓欣、利鲁唑片。报告期内，公司荣获“2025中国药品研发综合实力前50强”荣誉，恩元医学检验实验室获得上海市创新型中小企业荣誉证书；恩元医学检验实验室获得信息安全管理、质量管理、环境管理、职业健康安全管理四体系认证。","listedPrice":5.68},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恩华药业(002262)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恩华药业(002262)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恩华药业,002262,恩华药业股票,恩华药业股票老虎,恩华药业股票老虎国际,恩华药业行情,恩华药业股票行情,恩华药业股价,恩华药业股市,恩华药业股票价格,恩华药业股票交易,恩华药业股票购买,恩华药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恩华药业(002262)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恩华药业(002262)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}